Trial finds new drug safe, effective to treat deadliest form of epilepsy
MSN highlights UC trial data presentation
MSN highlighted research presented by the University of Cincinnati’s Brandon Foreman that found ganaxolone is a safe and effective treatment for refractory status epilepticus, the most severe and deadly form of epilepsy where seizures do not stop.
Current standards of care include administering an intravenous antiseizure medicine, a benzodiazepine such as midazolam, as soon as possible to stop seizures. When those do not work, a second intravenous antiseizure medication is started, but about one quarter of patients continue to experience seizures, termed refractory status epilepticus (RSE).
The Phase 3 RAndomized Therapy In Status Epilepticus (RAISE) trial tested a neurosteroid called ganaxolone for patients hospitalized with seizures that progressed to RSE despite receiving two or more antiseizure medications.
Researchers found a statistically significant proportion of patients who received ganaxolone stopped seizing within 30 minutes: 80% of those patients receiving ganaxolone saw their RSE stop a median of just 4 minutes after the drug was administered.
“Ganaxolone as a rapidly effective medication would fill a specific gap in care for which there are no current treatment options beyond intubation and anesthetic medications if standard antiseizure medications fail,” he said. “It is recognized that the use of anesthetics increases the morbidity and mortality of RSE, so ganaxolone has the potential to save lives and avoid prolonged intensive care.”
Featured photo at top of Foreman looking at a brain monitor. Photo/Andrew Higley/UC Marketing + Brand.
Related Stories
A legacy that leads: Honoring a beloved physician through the future of clinical medicine
March 31, 2026
After Cohen’s passing in 2023, the Harvey D. and Janet G. Cohen Charitable Foundation was established. With the establishment of the foundation, the Cohen trustees searched for a way to create lasting impact in Janet Cohen’s hometown while recognizing the compassion and dedication of her dear friend, Dr. Rouan.
Clear link discovered between chronic kidney disease and periodontal disease
March 31, 2026
Emerging evidence supports a relationship between chronic kidney disease and oral diseases, according to a recent review from University of Cincinnati College of Medicine researchers published in BMC Nephrology.
UC opens state-of-the-art zebrafish research facility to study infertility
March 31, 2026
The University of Cincinnati College of Medicine has opened a state-of-the-art zebrafish research facility in Cincinnati, Ohio. The Kossack Lab uses zebrafish to study infertility, reproductive health and how environmental contaminants impact human reproductive development.